| scholarly article | Q13442814 |
| P50 | author | Jaffer Ajani | Q64913003 |
| Stephen Swisher | Q89454225 | ||
| Lianchun Xiao | Q89992731 | ||
| Dipen Maru | Q91302122 | ||
| Homer A Macapinlac | Q98574158 | ||
| Manoop S Bhutani | Q102058874 | ||
| Wayne L. Hofstetter | Q107450763 | ||
| P2093 | author name string | Jeffrey H Lee | |
| Akihiro Suzuki | |||
| James Welsh | |||
| Steven H Lin | |||
| Yuki Hayashi | |||
| P2860 | cites work | The Hallmarks of Cancer | Q221226 |
| Influence of the baseline 18F-fluoro-2-deoxy-D-glucose positron emission tomography results on survival and pathologic response in patients with gastroesophageal cancer undergoing chemoradiation | Q44893920 | ||
| 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma | Q45073453 | ||
| Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study | Q46669666 | ||
| A prospective evaluation of the impact of 18-F-fluoro-deoxy-D-glucose positron emission tomography staging on survival for patients with locally advanced esophageal cancer | Q46742356 | ||
| Prediction of tumor response by FDG-PET: comparison of the accuracy of single and sequential studies in patients with adenocarcinomas of the esophagogastric junction. | Q53469770 | ||
| Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. | Q53520806 | ||
| FDG uptake, tumor proliferation and expression of glycolysis associated genes in animal tumor models | Q73537175 | ||
| Evaluation of esophageal cancers using fluorine-18-fluorodeoxyglucose PET | Q74650037 | ||
| Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group | Q77424043 | ||
| INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy | Q77706014 | ||
| Esophageal cancer | Q79620977 | ||
| Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer | Q79754864 | ||
| Clinical response to induction chemotherapy predicts local control and long-term survival in multimodal treatment of patients with locally advanced esophageal cancer | Q80852933 | ||
| Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinoma | Q81105996 | ||
| The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence | Q81290009 | ||
| Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 | Q27860674 | ||
| Outcomes of Patients With Esophageal Cancer Staged With [18F]Fluorodeoxyglucose Positron Emission Tomography (FDG-PET): Can Postchemoradiotherapy FDG-PET Predict the Utility of Resection? | Q34488764 | ||
| Classification of adenocarcinoma of the oesophagogastric junction | Q34755030 | ||
| Preoperative 18[F]-fluorodeoxyglucose positron emission tomography standardized uptake values predict survival after esophageal adenocarcinoma resection. | Q36401200 | ||
| Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. | Q36495076 | ||
| The importance of PET in the diagnosis and response evaluation of esophageal cancer | Q36636701 | ||
| Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. | Q36841557 | ||
| Chemoradiation in the management of esophageal cancer | Q36935105 | ||
| Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113 | Q37121698 | ||
| 18F-FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization | Q37440346 | ||
| Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging. The Visual Response Score and the Change in Total Lesion Glycolysis. | Q39666021 | ||
| The standardized uptake value of 18-fluorodeoxyglucose positron emission tomography after chemoradiation and clinical outcome in patients with localized gastroesophageal carcinoma | Q42941186 | ||
| Critical role of surgery in patients with gastroesophageal carcinoma with a poor prognosis after chemoradiation as defined by positron emission tomography | Q42971015 | ||
| The higher the decrease in the standardized uptake value of positron emission tomography after chemoradiation, the better the survival of patients with gastroesophageal adenocarcinoma | Q43593864 | ||
| Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging | Q43641822 | ||
| Worldwide esophageal cancer collaboration | Q44185301 | ||
| Adenocarcinoma of the esophagus: role of obesity and diet | Q44476677 | ||
| P433 | issue | 21 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | positron emission tomography | Q208376 |
| chemoradiotherapy | Q5090613 | ||
| P304 | page(s) | 4823-4833 | |
| P577 | publication date | 2011-03-31 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy | |
| P478 | volume | 117 |
| Q36328330 | 18-fluorodeoxy-glucose positron emission computed tomography as predictive of response after chemoradiation in oesophageal cancer patients |
| Q33798433 | 18F-deoxyglucose positron emission tomography/computed tomography to predict local failure in esophageal squamous cell carcinoma |
| Q49873949 | 18F-fluorodeoxyglucose positron emission tomography/computed tomography for the prediction of survival in patients with advanced esophageal cancer who have undergone neoadjuvant chemotherapy |
| Q36776993 | Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohort |
| Q64230448 | Can the Efficacy of [F]FDG-PET/CT in Clinical Oncology Be Enhanced by Screening Biomolecular Profiles? |
| Q40766240 | Change in chemotherapy during concurrent radiation followed by surgery after a suboptimal positron emission tomography response to induction chemotherapy improves outcomes for locally advanced esophageal adenocarcinoma. |
| Q38340526 | Clinical tools to predict outcomes in patients with esophageal cancer treated with definitive chemoradiation: are we there yet? |
| Q26753864 | Definitive, Preoperative, and Palliative Radiation Therapy of Esophageal Cancer |
| Q54652098 | Factors associated with local-regional failure after definitive chemoradiation for locally advanced esophageal cancer. |
| Q64067244 | Interobserver variability of image-derived arterial blood SUV in whole-body FDG PET |
| Q47650869 | Localized gastric cancer treated with chemoradation without surgery: UTMD Anderson Cancer Center experience |
| Q53665053 | Nomograms for prognostication of outcome in patients with esophageal and gastroesophageal carcinoma undergoing definitive chemoradiotherapy. |
| Q37320833 | Outcome of trimodality-eligible esophagogastric cancer patients who declined surgery after preoperative chemoradiation |
| Q58586449 | PET scan-directed chemoradiation for esophageal squamous cell carcinoma: no benefit for a change in chemotherapy in PET non-responders |
| Q47275072 | Pathological complete response in patients with esophageal cancer after the trimodality approach: The association with baseline variables and survival-The University of Texas MD Anderson Cancer Center experience |
| Q38824375 | Potentially Curable Cancers of the Esophagus and Stomach. |
| Q64940253 | Prediction and diagnosis of interval metastasis after neoadjuvant chemoradiotherapy for oesophageal cancer using 18F-FDG PET/CT. |
| Q37154079 | Prediction of outcome with FDG-PET in definitive chemoradiotherapy for esophageal cancer |
| Q53062665 | Prognostic impact of clinicopathological features and expression of biomarkers related to (18)F-FDG uptake in esophageal cancer. |
| Q36432120 | Prognostic significance of PET assessment of metabolic response to therapy in oesophageal squamous cell carcinoma |
| Q45887135 | Prognostic value of FDG uptake in primary inoperable non-small cell lung cancer |
| Q88990561 | Relationship Between Clinicopathological Characteristics and PET/CT Uptake in Esophageal Squamous Cell Carcinoma: [18F]Alfatide versus [18F]FDG |
| Q42414421 | Relationship between (18)F-fluorodeoxyglucose uptake in primary lesions and clinicopathological characteristics of esophageal squamous cell carcinoma patients |
| Q53086769 | Role of surgical resection in complete responders on FDG-PET after chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. |
| Q50635875 | Significance of baseline FDG-PET/CT scan as a method of staging regional lymph nodes in patients with operable distal oesophageal or gastroesophageal junction adenocarcinoma. |
| Q53165455 | Standardized uptake value by positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer. |
| Q38226697 | The application of functional imaging techniques to personalise chemoradiotherapy in upper gastrointestinal malignancies. |
| Q34401264 | The survival impact of XPA and XPC genetic polymorphisms on patients with esophageal squamous cell carcinoma |
| Q26864611 | The value of [18F]fluorodeoxyglucose-PET/CT in oesophageal cancer |
| Q87852624 | [Importance of PET in surgery of esophageal cancer] |
Search more.